Projected US Savings From Biosimilars, 2021-2025
Source : https://www.ajmc.com/view/projected-us-savings-from-biosimilars-2021-2025
Objectives: Biologics account for an increasing share of US prescription drug spending. Biosimilars could lower biologic prices through competition, but barriers to increasing both supply and uptake remain. We projected US biosimilar savings from 2021 to 2025 under different scenarios.
Conclusions: Biosimilar savings from 2021 to 2025 were $38.4 billion under our main assumptions. Greater savings may be feasible if managed care and other settings increase biosimilar utilization and promote competition.